Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.

@article{Zhai2003ClinicalPA,
  title={Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.},
  author={Suoping Zhai and Edward A. Sausville and Adrian M. Senderowicz and Yuichi Ando and Donna J. Headlee and Richard A. Messmann and Susan G. Arbuck and Anthony J. Murgo and Giovanni Melillo and Eiichi Fuse and William D. Figg},
  journal={Anti-cancer drugs},
  year={2003},
  volume={14 2},
  pages={
          125-35
        }
}
A phase I trial of flavopiridol administered as a 1-h i.v. infusion schedule was explored. Fifty-five patients were treated with flavopiridol at doses ranging from 12 to 78 mg/m2 daily for 5, 3 and 1 day every 3 weeks. Pharmacokinetic and pharmacodynamic analysis was performed together with analysis of a promoter polymorphism of the UGT1A1 gene. Peak concentrations and areas under the time-concentration curve of flavopiridol were linear within the doses studied. Estimated clearance was 13.8+/-4… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Rhabdoid tumor growth is inhibited by flavopiridol.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2008